Our study demonstrates that RyR2 activity determines the potency and efficacy of the open-state blockers FLEC and RPROP for suppressing arrhythmogenic Ca2+ waves in cardiomyocytes from WT mice, CPVT mouse models and rabbits. The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.